bioAffinity Technologies, Inc. (BIAF): Shareholders' Equity

Annual figures by period end, from SEC filings.

$7.28M
As of 2025-12-31
$3.77M
As of 2026-06-30
-13.0%
3-year compound annual growth
$11.04M2021-12-31: -$15.79M2022-12-31: $11.04M2023-12-31: $4.86M2024-12-31: $2.60M2025-12-31: $7.28M$7.28M
2021-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$7.28M+179.7%2026-03-16, Balance as of period end
2024-12-31$2.60M-46.4%2026-03-16, Balance as of period end
2023-12-31$4.86M-56.0%2025-03-31, Balance as of period end
2022-12-31$11.04Mn/m2024-04-01, Balance as of period end
2021-12-31-$15.79Mn/a2023-03-31, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
bioAffinity Technologies, Inc. (BIAF)2025-12-31$7.28M+179.7%
Absci Corp (ABSI)2025-12-31$189.45M+5.8%
Foxo Technologies Inc. (FOXO)2025-12-31$11.14M+109.3%
OmniAb, Inc. (OABI)2025-12-31$267.03M-7.2%
iSpecimen Inc. (ISPC)2025-12-31$3.09M-6.7%
OneMedNet Corp (ONMD)2025-12-31-$2.96Mn/m
MaxCyte, Inc. (MXCT)2025-12-31$171.49M-16.9%
Cannabis Bioscience International Holdings, Inc. (CBIH)2025-05-31-$1.16Mn/m
NRC Health (NRC)2025-12-31$13.99M-55.3%

Compare BIAF, ABSI, FOXO, OABI side by side · Screen every company in Services-Commercial Physical & Biological Research ↗